Lung cancer patients get early access to promising drug before approval
NCT ID NCT04830202
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This program offers early access to telisotuzumab vedotin for people with non-small cell lung cancer who have no other suitable treatments and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by regulators.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.